Trial Profile

Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imiquimod (Primary) ; Programmed cell death 1 receptor modulators
Indications Solid tumours; Uveal melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms AM-003

Most Recent Events

14 Jul 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Unable to enroll enough patients to complete targeted enrollment in a reasonable time.
03 Aug 2023 Planned End Date changed from 30 Jun 2025 to 1 Feb 2024.
03 Aug 2023 Planned primary completion date changed from 31 Dec 2024 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com